Global Meglinitides Market, By Indication (Type II Diabetes, Others), Drugs (Repaglinide, Nateglinide, Mitiglinide, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Meglinitides Market Analysis and Size
The global meglinitides market is expected to witness significant growth during the forecast period. Rising prevalence of type 2 diabetes worldwide and emerging markets are the factors responsible for the growth of this market. Researchers are developing new drugs that are helpful in boosting up the market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global meglinitides market in the forecast period 2022-2029. The expected CAGR of global meglinitides market is tend to be around 3.0% in the mentioned forecast period. The market was valued at USD 3.94 billion in 2021, and it would grow upto USD 5 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Meglinitides are the agents used to treat type 2 diabetes. They act same as β-cell receptor as sulphonylureas, but have a different chemical structure. They are novel class of non-sulfonylurea insulin secretagogues characterized by very rapid onset and abbreviated duration of action. They act by stimulating pancreas to release insulin in response to meal. In functioning pancreatic beta cells, it also closes ATP-dependent potassium dependent channels. Due to this depolarization of beta cells, opening of calcium channels resulting in influx of calcium and Increased intracellular calcium induces insulin secretion. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Indication (Type II Diabetes, Others), Drugs (Repaglinide, Nateglinide, Mitiglinide, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.), GSK Plc. (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India)
|
|
Market Opportunities
|
|
Global Meglinitides Market Dynamics
Drivers
- Rising Awareness For Disease Treatment
Rising awareness among patients and healthcare professionals for the treatment of diabetes and more and more usage of combination therapy are the driving factors that is expected to boost the demand for global diabetic nephropathy market during the forecast period of 2022-2029.
- Increase in the prevalence of type 2 diabetes
As per the reports of International Diabetes Federation (IDF), the adult diabetes population is approximately 537 million in 2021, and this number is rising high to 643 million in 2030. Many factors such as obesity, unhealthy diet, and physical inactivity are increasing the cases of Type 1 and Type 2 diabetes cases. The increasing prevalence of diabetic patients are indications of the increasing usage of meglinitides.
Opportunities
- Increasing Demand for Retail Pharmacies
The increase in the number of retail pharmacies in developed countries, as well as the increase in the number of anti-diabetic medications delivered through them, creates opportunities for market growth. Furthermore, patients prefer retail pharmacies for drug purchases because they are more convenient.
- Increasing in Elderly Population
As per the reports of European Society of Cardiology, the total disease burden approximately was around 39.7% due to increasing population growth and ageing. Increase in geriatric population has boosted to significant diabetes burden.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global meglinitides market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global meglinitides market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global meglinitides market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Meglinitides Market
The Covid-19 pandemic negatively impacted the global meglinitides market because the utmost priority was given to Covid-19 patients for treatment. Diabetes and uncontrolled hyperglycemia are poorly associated with patients having COVID-19, including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the meglitinide market's growth globally.
Global Meglinitides Market Scope
The global meglinitides market is segmented on the basis of indication, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Type II Diabetes
- Others
Drugs
- Repaglinide
- Nateglinide
- Mitiglinide
- Others
Route of Administration
- Oral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Meglinitides Market Regional Analysis/Insights
The global meglinitides market is analysed and market size insights and trends are provided by indication, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global meglinitides market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacturer of the product, high research and development and healthcare expenditure and skilled professionals.
Asia Pacific dominates the market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Meglinitides Market Share Analysis
The global meglinitides market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global meglinitides market.
Key players operating in the global meglinitides market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
SKU-